Systematic (IUPAC) name | |
---|---|
(1R,2S)-3-[-2-amino-1-hydroxy-propyl]phenol | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Pregnancy cat. | C(AU) C(US) |
Legal status | POM (UK) |
Routes | Intravenous |
Pharmacokinetic data | |
Bioavailability | n/a |
Protein binding | ~45% |
Metabolism | Hepatic |
Identifiers | |
CAS number | 54-49-9 |
ATC code | C01CA09 |
PubChem | CID 5906 |
DrugBank | APRD00555 |
ChemSpider | 5695 |
UNII | 818U2PZ2EH |
KEGG | D08192 |
ChEBI | CHEBI:6794 |
ChEMBL | CHEMBL1201319 |
Chemical data | |
Formula | C9H13NO2 |
Mol. mass | 167.205 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Metaraminol (INN, trade name Aramine) is a potent sympathomimetic amine used in the prevention and treatment of hypotension, particularly as a complication of anesthesia. It is an α1-adrenergic receptor agonist with some β effect.
Metaraminol is also used in the treatment of priapism. Although not approved for this use, it appears to be effective.[1][2][3]
Metaraminol, L-1-(3-hydroxyphenyl)-2-aminopropan-1-ol, is synthesized in two ways. The first way is synthetic, and it is from 3-hydroxypropiophenone. The hydroxyl group is protected by alkylation with benzyl chloride, giving 3-benzyloxypropiophenone. Upon reaction with butyl nitrite, it undergoes nitrosation into the isonitrosoketone, which by reduction using hydrogen over Raney nickel turns into 1-(3-benzyloxyphenyl)-2-aminopropan-1-ol, the protecting benzyl group is removed by reduction using hydrogen over palladium catalyst, to give racemic metaraminol. The desired L-isomer is isolated with the help of (+)-tartaric acid.
The second way is semisynthetic, consisting of fermentation of D-glucose in the presence of 3-acetoxybenzaldehyde, which forms (-)-1-hydroxy-1-(3-hydroxyphenyl)-acetone, the carbonyl group of which is reduced by hydrogen over a palladium catalyst in the presence of ammonia, giving metaraminol.
|